Evidence map›Paper›PMID 42106467›Full record

ArticleScientific reports2026

Optimizing Zirconium-89 labeling for chimeric antigen receptor T cell PET imaging by comparing desferrioxamine and oxine.

Nare Ko, Seog-Young Kim, Sang Ju Lee, Hyunsu Soh, Hyori Kim, Ji-Min Ju, Sang-Jin Lee, Junho Chung, Seung Jun Oh, Jin-Sook Ryu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nare Ko *Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Seog-Young Kim *Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Sang Ju LeeDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hyunsu SohAsan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Hyori KimAsan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
Ji-Min JuImmunotherapeutics Branch, Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, Republic of Korea.
Sang-Jin LeeImmunotherapeutics Branch, Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, Republic of Korea.
Junho ChungDepartment of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Seung Jun OhDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jin-Sook RyuDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. jsryu2@amc.seoul.kr.

Funding

the Korea Health Technology R&D Project RS-2018-KH049510the Ministry of Food and Drug Safety 17172MFDS212
6 · The paper itself

Abstract

This study aimed to optimize Zirconium-89 (

Indexed as

DeferoxamineOxyquinolinePositron-Emission TomographyRadioisotopesReceptors, Chimeric AntigenT-LymphocytesZirconiumCell ProliferationCell SurvivalHumansOrganometallic CompoundsDeferoxamineindium oxineOrganometallic CompoundsOxyquinolineRadioisotopesReceptors, Chimeric AntigenZirconiumZirconium-89CAR-T cellCell therapyCell trackingDirect cell labelingPositron emission tomographyZirconium-89 labeling

Identifiers

PMID42106467
PMCPMC13346837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.